US judge says Astellas Pharma’s Myrbetriq patent not proven indefinite under heightened standard
Generic drugmakers Lupin and Zydus Pharmaceuticals suffered an early loss today in their bid to invalidate a patent associated with the bladder control drug Myrbetriq when a US judge in Delaware...To view the full article, register now.
Already a subscriber? Click here to view full article